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incremental cost of HUF 143,897 over standard care. This addi-
tional cost of care resulted in an incremental 0.05 QALY gain
over the 6 months period. The incremental cost effectiveness
ratio was 2,863,913 HUF/QALY for the pimecrolimus therapy.
CONCLUSIONS: Pimecrolimus is more cost-effective than
many other health care interventions currently reimbursed by the
Hungarian National Health Fund.
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OBJECTIVES: To evaluate short-term and long-term cost-
effectiveness of imiquimod versus surgery in the treatment of
superﬁcial basal cell carcinoma in The Netherlands. METHODS:
A decision analytic model adopting a societal perspective was
developed and compared cost and outcomes of imiquimod vs.
surgery. The short-term (18 weeks) effectiveness outcome was
histological clearance, with sustained clearance the outcome at
3 years. Direct costs included costs of excision and Moh’s
surgery, drugs, adverse events, follow-up and transportation.
Indirect costs comprise working hours lost due to dermatologist
and surgery visits. Data were derived from clinical trials
(Imiquimod histological clearance and recurrence rates), Delphi
panel (resource utilisation) and published literature (surgery
response and recurrence rates). Cost data were taken from ofﬁ-
cial costing guide and tariff lists. Two scenarios were used for
calculating surgery costs: 1) micro-costing (using average time
and supplies obtained from the Delphi panel), and 2) a Dutch
study on the costs of surgery. Long-term costs were discounted
at 4%. RESULTS: Compared with surgery, short-term savings
with imiquimod were €79 and €97 per patient for scenarios 1
and 2 respectively [total costs: €585 vs. €663 and €590 vs. €687].
Histological clearance of 82% for imiquimod and 91% for
surgery made imiquimod a cost-effective treatment option. Long-
term costs with imiquimod were an extra €148 and €133 for 
scenarios 1 and 2 [total costs: €1471 vs. €1322 and €1479 vs.
€1346], while sustained clearance with imiquimod was 87% vs.
96% for surgery. The model showed moderate sensitivity to
changes in response and recurrence rates, response to treatment,
and numbers of working days lost. CONCLUSION: While
imiquimod is cost-effective in the short-term, long-term cost-
effectiveness should be judged with prudence because of the
uncertainty surrounding long-term recurrence data. Non-tangi-
ble beneﬁts, such as patient preference for avoiding surgery and
patient convenience were not quantiﬁed in the model either.
PSN5
PSN6
COST-EFFECTIVENESS OF BRIVUDINE COMPARED TO
ACICLOVIR FOR THE TREATMENT OF HERPES ZOSTER IN
GERMANY
Kaltwasser MT1, Nannicini A2,Tofani L2
1Berlin-Chemie (Menarini Group), Berlin, Germany; 2A. Menarini,
Florence, Italy
OBJECTIVES: To examine the cost-effectiveness (CE) of brivu-
dine over aciclovir in the treatment of herpes zoster in Germany.
METHODS: This CE analysis used effectiveness data from a
double-blind RCT comparing brivudine (125mg p.o. once daily)
with aciclovir (800mg p.o. ﬁve times daily). Treatment with
brivudine showed a 25% reduction in postherpetic neuralgia
(PHN). Based on the IMS prescription index, the 2004 incidence
of herpes zoster in Germany was 348,000 cases, with 15.74%
consecutive cases of PHN under brivudine and 21% PHN cases
under aciclovir. Cost data were obtained from public price lists.
One therapy cycle with brivudine or aciclovir costs €95.67 and
€32.83 respectively; analgesics for PHN cost an average €1500
annually. The study was conducted considering direct costs only.
A sensitivity analysis accounted for varying costs for treating
PHN and age-dependent PHN incidences. RESULTS: A total of
54,775 PHN cases under brivudine and 73,080 cases under aci-
clovir were calculated, producing total annual treatment costs of
€115,455,660 and €121,044,840. Treatment with brivudine
saved costs of €305.34 per PHN case avoided. The sensitivity
analysis considered that 60% of herpes zoster patients are 60
years or older (IMS Disease Analyzer 2002), resulting in differ-
ent numbers of PHN cases depending on age and antiviral
therapy. ICERs of brivudine ranged for the older age group
between €694.66 (PHN therapy cost: €500) and -€1805.34
(PHN therapy cost: €3000). Corresponding values for the
younger age group were €1827.66 and -€672.34. Both antiviral
therapies produced equal annual total therapy costs if PHN
therapy amounted to €1200. CONCLUSIONS: Although three
times more expensive, brivudine proved cost effective over aci-
clovir, producing savings if PHN therapy costs were equal to or
higher than €1200. Since effective analgesic therapy would cost
an average €3000 annually, brivudine may be recommended as
ﬁrst-choice treatment because of its cost-saving potential and
convenient once-daily dosage.
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OBJECTIVES: To estimate the annual number and frequency of
medical consultations for EGW in dermatology, gynecology,
proctology and in Sexually Transmitted Disease Clinics (STDC)
in France. METHODS: This is an observational study with
patients recruited prospectively from representative physicians
samples. Data related to the management of EGW was retrieved
for all patients suffering from EGW and willing to take part in
the study, during one 2-week period in June 2004. RESULTS:
The patients (n = 308) were recruited by the physician sample
that included 198 gynecologists, 102 dermatologists, 50 proc-
tologists and 122 physicians working in 51 STDCs. The annual
number of consultations for EGW is estimated at 423,751 (36%
for dermatologists, 53% for gynecologists, 6% for proctologists,
5% in STDC). The annual number of visits for a new episode of
EGW amounted to 160,247, representing 38% of the consulta-
tions. The annual frequency of consultation is 1,1 to 1.4% for
dermatologists and gynecologists and 4.4% to 5.1% for proc-
tologists. Almost half of the patients (43%) were seeking care
because of an EGW recurrence. EGW are treated using phar-
macological treatments and in-ofﬁce procedures (electrocoagu-
lation, cryotherapy, surgery, laser). Imiquimod treatment is used
as ﬁrst-line therapy is 40% of patients with a ﬁrst episode of
EGW and in 38% of patients presenting for an EGW recurrence.
CONCLUSION: Gynecologists are the most consulted special-
ists for EGW and proctologists have the highest annual fre-
quency of consultation. Various treatments are used to manage
EGW patients.
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OBJECTIVE: The American Academy of Dermatology guide-
lines provide a standard for appropriate pharmacological
therapy in psoriasis treatment. This survey study examined if
patients with severe psoriasis were on appropriate medications.
METHODS: A survey for this study was conducted by the
National Psoriasis Foundation between November and Decem-
ber 2004. A total of 400 interviews (telephone n = 188 and
online n = 212) were held with psoriasis and psoriatic arthritis
respondents. The respondents were asked questions regarding
their psoriasis. Some of these pertained to the type of medica-
tion participants were currently using. Respondents chosen from
a random sample were screened for a mix of gender and age.
Severity was categorized according to self-reported body surface
area involvement. Descriptive data were generated to determine
demographic characteristics of study population and prescrip-
tion patterns. RESULTS: Approximately 55% of the population
had severe psoriasis. Almost 50% of the population was on
topical therapy while 32% of the study sample was using sys-
temic medications for their psoriasis. About 19% of the study
population indicated that they were currently not on any treat-
ment. Almost 54% of these were suffering from severe psoria-
sis. A total of 157 patients with severe psoriasis were on some
form of topical therapy, however, only 63 of these were on con-
current recommended systemic therapy. As much as 60% of the
patients with severe psoriasis were on some form of topical
therapy alone to treat their psoriasis. CONCLUSIONS: Even
with such easily accessible guidelines in place, this study ﬁnds
that there are several people suffering from severe psoriasis that
are not on the recommended therapy in the United States. There
remains a need to inform both the patients and physicians about
appropriate pharmacotherapy to avoid further worsening of
health status of the patients involved.
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OBJECTIVES: To examine one-year patterns of topical acne pre-
scription medication use among enrollees of a US national phar-
macy beneﬁts management system. METHODS: We conducted
a one-year, retrospective, longitudinal cohort study of pharmacy
claims (i.e., prescription ﬁlls) for topical acne prescription med-
ications among continuously enrolled patients with at least one
claim for: retinoids (tazarotene, retinoic acid) or antimicrobials
(erythromycin, erythromycin with benzoyl peroxide, clin-
damycin, clindamycin with benzoyl peroxide, azelaic acid, 
sulfacetamide, benzoyl peroxide). We examined patient charac-
teristics (age, gender), proportion of patients using topical med-
ications as monotherapy or in combination with other targeted
medications, and average number of targeted medication claims
per patient. RESULTS: Among 76,407 identiﬁed patients, 11.4%
were under age 14, 35.3% age 14 to 17 years, 19.1% age 18 to
24 years, 9.2% age 25 to 31 years, 8.3% age 32 to 38 years,
6.9% age 39 to 45 years, and 9.8% over 45 years. Sixty-four
percent were female. Three quarters (74%) of patients used only
one targeted topical acne medication (i.e., monotherapy)
throughout the index year. Among patients receiving monother-
apy, total average number of claims was 2.3 (erythromycin, 1.7
claims; erythromycin with benzoyl peroxide, 2.4; clindamycin
2.8; clindamycin with benzoyl peroxide 2.7; azelaic acid, 2.3;
benzoyl peroxide, 2.8; sulfacetamide, 1.9; retinoids, 2.0). Among
patients receiving combined therapy, total average number of
antimicrobial claims was 2.2 and total number of retinoid claims
was also 2.2 Number of claims, types of topical acne prescrip-
tion medications, and other patterns of use did not signiﬁcantly
differ by age or gender. CONCLUSIONS: Overall, patients had
approximately two targeted prescriptions ﬁlls over a one-year
index period. Rates of prescription ﬁlls did not differ by class of
medication, patient age, or gender. Assumptions that females or
older patients are more compliant with their topical prescription
acne regimens were not supported by our ﬁndings.
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OBJECTIVE: In spite of a signiﬁcant growth in comparatively
inexpensive generic medications, the bioavailability concerns
associated with dermatological drugs make the generic substitu-
tion practices controversial for skin conditions. The objective of
this study was to analyze the trends in branded and generic drugs
used in dermatological conditions from 1990–2003. It also ana-
lyzed the overall trend in branded and generic drugs in the United
States. METHODS: A number of summary databases including
the National Ambulatory Medical Care Survey (NAMCS), NDC
Health Corporation’s Pharmaceutical Audit Suite (PHAST)
database, and the Food and Drug Administration resources from
1990–2003 were analyzed to obtain and compare information
on the manufacturing, production, patents and prescription 
of branded and generic drugs. These data were examined to
